Literature DB >> 429321

Inactivation of rat renal phosphate-dependent glutaminase with 6-diazo-5-oxo-L-norleucine. Evidence for interaction at the glutamine binding site.

R A Shapiro, V M Clark, N P Curthoys.   

Abstract

Inactivation of rat renal phosphate-dependent glutaminase by 6-diazo-5-oxo-L-norleucine occurs only under conditions where the enzyme is catalytically active. The glutaminase activity and the rate of inactivation by the diazoketone exhibit very similar phosphate concentration-dependent activation profiles. Because of this phosphate dependency, it was not possible to differentiate an apparent protection by glutamine from the strong inhibition of inactivation caused by glutamate. The ability of glutamate to protect the glutaminase against inactivation is reversed by increasing concentrations of phosphate. The observed characteristics of inactivation by 6-diazo-5-oxo-L-norleucine differ considerably from those reported for the inactivation by L-2-amino-4-oxo-5-chloropentanoic acid. In addition, the presence of o-carbamoyl-L-serine was found to stimulate inactivation by 6-diazo-5-oxo-L-norleucine, but to protect the glutaminase against inactivation by the chloroketone. Preinactivation of the glutaminase by the diazoketone only slightly reduced the stoichiometry of binding of [5-14C]chloroketone. These observations suggest that 6-diazo-5-oxo-L-norleucine and L-2-amino-4-oxo-5-chloropentanoic acid interact with different sites on the glutaminase which are specific for binding glutamine and glutamate, respectively.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 429321

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  33 in total

1.  Glutamine targeting inhibits systemic metastasis in the VM-M3 murine tumor model.

Authors:  Laura M Shelton; Leanne C Huysentruyt; Thomas N Seyfried
Journal:  Int J Cancer       Date:  2010-11-15       Impact factor: 7.396

2.  Evaluating the Analgesic Effect of the GLS Inhibitor 6-Diazo-5-Oxo-L-Norleucine in Vivo.

Authors:  Heith A Crosby; Kenneth E Miller
Journal:  Pharm Pharmacol Int J       Date:  2016-01-08

3.  Mechanism by which a recently discovered allosteric inhibitor blocks glutamine metabolism in transformed cells.

Authors:  Clint A Stalnecker; Scott M Ulrich; Yunxing Li; Sekar Ramachandran; Mary Kate McBrayer; Ralph J DeBerardinis; Richard A Cerione; Jon W Erickson
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-29       Impact factor: 11.205

4.  Bioanalysis of 6-diazo-5-oxo-l-norleucine in plasma and brain by ultra-performance liquid chromatography mass spectrometry.

Authors:  Jesse Alt; Michelle C Potter; Camilo Rojas; Barbara S Slusher
Journal:  Anal Biochem       Date:  2015-01-10       Impact factor: 3.365

5.  Intracellular localization and properties of phosphate-dependent glutaminase in rat mesenteric lymph nodes.

Authors:  M S Ardawi; E A Newsholme
Journal:  Biochem J       Date:  1984-01-01       Impact factor: 3.857

6.  Evaluating the Toxicity of the Analgesic Glutaminase Inhibitor 6-Diazo-5-Oxo-L-Norleucine in vitro and on Rat Dermal Skin Fibroblasts.

Authors:  Heith A Crosby; Michael Ihnat; Kenneth E Miller
Journal:  MOJ Toxicol       Date:  2015-03-25

Review 7.  The molecular rationale for therapeutic targeting of glutamine metabolism in pulmonary hypertension.

Authors:  Thomas Bertero; Dror Perk; Stephen Y Chan
Journal:  Expert Opin Ther Targets       Date:  2019-05-11       Impact factor: 6.902

8.  Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis.

Authors:  Yan Xiang; Zachary E Stine; Jinsong Xia; Yunqi Lu; Roddy S O'Connor; Brian J Altman; Annie L Hsieh; Arvin M Gouw; Ajit G Thomas; Ping Gao; Linchong Sun; Libing Song; Benedict Yan; Barbara S Slusher; Jingli Zhuo; London L Ooi; Caroline G L Lee; Anthony Mancuso; Andrew S McCallion; Anne Le; Michael C Milone; Stephen Rayport; Dean W Felsher; Chi V Dang
Journal:  J Clin Invest       Date:  2015-04-27       Impact factor: 14.808

9.  Design, synthesis, and pharmacological evaluation of bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 3 (BPTES) analogs as glutaminase inhibitors.

Authors:  Krupa Shukla; Dana V Ferraris; Ajit G Thomas; Marigo Stathis; Bridget Duvall; Greg Delahanty; Jesse Alt; Rana Rais; Camilo Rojas; Ping Gao; Yan Xiang; Chi V Dang; Barbara S Slusher; Takashi Tsukamoto
Journal:  J Med Chem       Date:  2012-11-30       Impact factor: 7.446

10.  GABA synthesis in brain slices is dependent on glutamine produced in astrocytes.

Authors:  G Battaglioli; D L Martin
Journal:  Neurochem Res       Date:  1991-02       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.